Track topics on Twitter Track topics that are important to you
Vitae Pharmaceuticals is an emerging pharmaceutical company with two compounds in human clinical trials, a broad portfolio of late stage preclinical programs and an underlying pipeline of discovery programs. Vitae's goal is to discover, develop and commercialize innovative new medicines that will be best-in-class for important disease areas, such as cardiovascular diseases, cancer and dermatology.We are focused on the development of compounds for high value, well validated biological targets. In our discovery and development processes, we seek to leverage available existing clinical and / or preclinical knowledge to efficiently and effectively create novel drug candidates that can address clear unmet therapy needs. Vitae's unique product engine combines the drug discovery skills of proven, deeply experienced drug hunters with state-of-the-art proprietary drug design technologies. This integrated and entrepreneurial approach improves the quality and innovativeness of the compounds we discover, while dramatically shortening the time required to bring them to the clinic.We have demonstrated the ability to rapidly advance novel compounds into clinical development, as Vitae now has clinical candidates in three therapeutic areas, two of which are in clinical studies and a pipeline of additional promising compounds.
502 West Office Center
Drive Fort Washington
United States of America
Phone: (215) 461-2000
Fax: (215) 461-2006
* Vitae pharmaceuticals achieves proof-of-concept with first-in-class roryt inhibitor in moderate to severe psoriasis
Fort Washington, Pa.-based Vitae Pharmaceuticals is aiming to secure $40 million in a public stock offering. -More-
Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) raised $35 million through the sale of 5.8 million shares at $6 in a follow-on underwritten by Piper Jaffray, BMO Capital Markets and Wedbush PacGrow. It propo...
Vitae Pharmaceuticals said its VTP-43742 psoriasis drug significantly reduced the skin condition in patients in phase 2a clinical trial.
A public stock offering has secured $35 million for Vitae Pharmaceuticals. -More-
Two weeks after a stock downturn due to questions about the early closing of Phase IIa enrollment for its first-in-class psoriasis candidate, Vitae Pharmaceuticals Inc. bounced back March 16 with data...
Vitae Pharmaceuticals Inc. (biotech focusing on unmet needs) netted $32.9mm in a follow-on public offering (off of a shelf filing) of 5.8mm shares at $6.00. Proceeds will be used to advance clinical ...
March 16 (Reuters) - Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial.
Retinoic acid receptor-related orphan nuclear receptor gamma t (RORγt or RORC2) is a key transcription factor for the differentiation of naïve proinflammatory CD4(+) T cells and the production of T ...
Advanced practice nurses (APNs) should maintain a curriculum vitae (CV) that comprehensively reflects the individual's work and professional accomplishments. This article guides APNs through best prac...
This study compared the removal of pharmaceuticals from secondary effluents of wastewater treatment plants (WWTPs) by conventional ozonation and the electro-peroxone (E-peroxone) process, which involv...
A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have bee...
The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of primary liver tumors in clinical study phase I and II. The study will ...
Vitae Pharmaceuticals is a development-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets, including...
Vitae Pharmaceuticals is an emerging pharmaceutical company with two compounds in human clinical trials, a broad portfolio of late stage preclinical programs and an underlying pipeline of discovery pr...
The CV Index provides a permanent, web presence & management centre for your Curriculum Vitae (Resume), which is freely searchable on our powerful CVs search engine, wherever you are in the world. Ch...
Our Profile represents an introductory overview of the key facts investors need to know about BB MEDTECH. The various ticker symbols are also available here. Click on Board of Directors and Management...
BitTech, Inc. is a biotechnology company that focuses on the identification and initiation of research which has the potential to lead to enabling technology. BitTech was founded by Grant A. Bitter, ...
We have published hundreds of Vitae Pharmaceuticals news stories on BioPortfolio along with dozens of Vitae Pharmaceuticals Clinical Trials and PubMed Articles about Vitae Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vitae Pharmaceuticals Companies in our database. You can also find out about relevant Vitae Pharmaceuticals Drugs and Medications on this site too.
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...